Afghanistan vs Sudan: Statin use vs. average non-HDL cholesterol levels
Afghanistan
3.1
in 2018
Sudan
3.1
in 2018
Afghanistan rank
134th
Sudan rank
134th
Statin use vs. average non-HDL cholesterol levels over time
- Afghanistan
- Sudan
How they compare
Afghanistan currently reports 3.1 against 3.1 in Sudan, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Afghanistan ahead.
Afghanistan ranks 134th and Sudan ranks 134th of 191 countries.
Afghanistan has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Afghanistan | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.98 | 2.61 | 0.37 | Afghanistan |
| 1990s | 3.1 | 2.72 | 0.38 | Afghanistan |
| 2000s | 3.1 | 2.82 | 0.28 | Afghanistan |
| 2010s | 3.1 | 2.98 | 0.1222 | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Afghanistan or Sudan?
- Afghanistan, at 3.1 against 3.1 in Sudan as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Afghanistan and Sudan?
- 0, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Sudan?
- 39 years are reported by both, from 1980 to 2018.
- How do Afghanistan and Sudan rank globally for statin use vs. average non-hdl cholesterol levels?
- Afghanistan ranks 134th and Sudan ranks 134th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.